Pharmacyclics Earnings: Here’s Why Investors Don’t Like These Results

Revenue decreased 43.56% from $102.7 million in the previous quarter. EPS decreased 45.1% from $1.02 in the previous quarter.

Looking Forward: Analysts have a more positive outlook for the company’s next-quarter performance. Over the past three months, the average estimate for next quarter’s earnings has risen from a loss of $0.19 to a loss $0.16. For the current year, the average estimate has moved up from a profit of $0.64 to a profit of $0.71 over the last ninety days.

Stocks with improving earnings metrics are worthy of your extra attention. In fact, “E = Earnings Are Increasing Quarter-Over-Quarter” is a core component of our CHEAT SHEET investing framework for this very reason. Don’t waste another minute – click here and get our CHEAT SHEET stock picks now.

(Company fundamentals provided by Xignite Financials. Email any earnings discrepancies to earnings [at] wallstcheatsheet.com)